Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
Cagrilintide has the potential for the research of obesity.
Expiry Date 12 months GLP1R (Glucagon-Like Peptide 1 Receptor (GLP1R)) Alternative Name GLP-1 Receptor Background Glucagon-like peptide 1 receptor, GLP-1 receptor, GLP-1-R, GLP-1R Gene ID 2740 UniProt P43220 Pathways Positive Regulation of Peptide Hormone Secretion, Hormone Transport, cAMP Metabolic Process, Feeding Behaviour Target
Guidance on heart rate monitoring in the context of GLP-1-based therapies is currently derived from the SmPCs of approved comparator agents
Scott Bunce The study used smartphone apps to track cravings in real-time throughout the day
US$ 26.71
US$ 26.40
US$ 21.59
US$ 25.31
US$ 20.43
